Novel Application of Cell Penetrating R11 Peptide for Diagnosis of Bladder Cancer

Du, Yiqing; Wang, Lei; Wang, Weiyi; Guo, Ting; Zhang, Mengzhao; Zhang, Pu; Zhang, Yanning; Wu, Kaijie; Li, Axing; Wang, Xinyang; He, Jiankang; Fan, Jinhai

doi:10.1166/jbn.2018.2499

Cited by 14 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 Unlike gene therapy using viral method, these vectors are internalized into cells through lipid raftdependent macropinocytosis rather than endocytosis and specific receptor as in the CAR. 43,44 p53 transcription factor composed of 3 domains; activation domain, sequence-specific DNA binding domain, and oligomerization domain. There are 2 sequence-specific DNA binding domains.…”

Section: Non-viral Methodsmentioning

confidence: 99%

“…Besides, some of them were entrapped in macropinosome which hindered them to be fused into the target region. 44,48 However, recent research on haemagglutinin-2 protein had shed light that may lead us to solution of this problem. This NH2-terminal 20 amino acid peptide of the influenza virus haemagglutinin-2 protein (HA-2) with its pH-based fusogenicity got the entrapped 11R-p53 to be released from macropinosome so that the molecule could swim right through towards the target region, and got fused with the mt-p53 C-terminus at pH 5, thus turning on the latent p53 protein to action.…”

Section: Non-viral Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Manipulation of p53 Protein in Bladder Cancer Treatment

Mansor¹

2021

imjm

View full text Add to dashboard Cite

Chemotherapy and radiotherapy are gold standard treatment for bladder cancer (BC) for over 50 years. The efficacy on early stage BC patients is virtuous. However, patients with aggressive cancer growth benefited less from the therapy. Aberrant p53 was found in more than 50% of high-grade BC patients. Therefore, targeting p53 in a subset of high-grade BC patients expressing aberrant p53 is a promising strategy. In this paper, p53 role in BC carcinogenesis is discussed. Followed by p53-targeting strategies in current BC treatment. Besides, p53-targeting strategies that have been implemented in other types of cancer and their potential to be adapted in BC will be deliberated. Although targeting p53 is promising, none of the strategies studied were successfully implemented in healthcare settings. Restoration of p53 as the guardian of the genome is an exciting area for translational research. It has potential to replace the genotoxic chemotherapy and radiotherapy, thus, eliminating the notorious painful sideeffects on a subset of high-grade BC patients. Searches were performed on PubMed and Google Scholar web using the keywords “bladder cancer” or “urothelial cancer” or “urothelial cell carcinoma” and “p53”. Only full papers of research articles and review papers were included for analysis. Papers were categorized as either p53 function, current treatment using p53 and future potential treatment using p53 for details analysis.

show abstract

Section: Non-viral Methodsmentioning

confidence: 99%

Section: Non-viral Methodsmentioning

confidence: 99%

Manipulation of p53 Protein in Bladder Cancer Treatment

Mansor¹

2021

imjm

View full text Add to dashboard Cite

show abstract

“…Nuclear targeting Has certain cytotoxicity May be a delivery vector for agents used in treating bladder diseases. [ 36 , 42 ] …”

Section: Screening Of Peptidementioning

confidence: 99%

Advances in Research on Bladder Cancer Targeting Peptides: a Review

Zheng

Zhang

Wang

et al. 2021

Cell Biochem Biophys

Self Cite

View full text Add to dashboard Cite

Bladder cancer (Bca) is the second most common malignant tumor of the genitourinary system in Chinese male population with high potential of recurrence and progression. The overall prognosis has not been improved significantly for the past 30 years due to the lack of early theranostic technique. Currently the early theranostic technique for bladder cancer is mainly through the intravesical approach, but the clinical outcomes are poor due to the limited tumor-targeting efficiency. Therefore, the targeting peptides for bladder cancer provide possibility to advance intravesical theranostic technique. However, no systematic review has covered the wide use of the targeting peptides for intravesical theranostic techniques in bladder cancer. Herein, a summary of original researches introduces all aspects of the targeting peptides for bladder cancer, including the peptide screening, the targeting mechanism and its preclinical application.

show abstract

“…This selectivity can also be utilised to deliver imaging agents to tumour cells. For example, Du et al found that the oligoarginine, R11, is able to deliver a fluorescent probe to bladder tumours, producing a more intense signal than that seen in normal bladder tissue [26]. More extensive reviews of the applications of CPPs as anti-cancer therapies and diagnostics can be found in [22] and [23].…”

Section: Applicationsmentioning

confidence: 99%